Vir Biotechnology
215 hedge funds and large institutions have $783M invested in Vir Biotechnology in 2024 Q2 according to their latest regulatory filings, with 34 funds opening new positions, 75 increasing their positions, 72 reducing their positions, and 25 closing their positions.
38% more call options, than puts
Call options by funds: $2.65M | Put options by funds: $1.92M
36% more first-time investments, than exits
New positions opened: 34 | Existing positions closed: 25
3% more funds holding
Funds holding: 209 → 215 (+6)
4% more repeat investments, than reductions
Existing positions increased: 75 | Existing positions reduced: 72
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
9% less capital inflows, than outflows
Capital inflows: $84.4M | Capital outflows: $92.3M
1.15% less ownership
Funds ownership: 65.83% → 64.67% (-1.2%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OrbiMed
New York
|
+$16.1M |
| 2 |
JP Morgan Chase
New York
|
+$7.6M |
| 3 |
Millennium Management
New York
|
+$5.82M |
| 4 |
Voloridge Investment Management
Jupiter,
Florida
|
+$5M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$4.54M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$25.5M |
| 2 |
State Street
Boston,
Massachusetts
|
-$18.9M |
| 3 |
Citigroup
New York
|
-$9.97M |
| 4 |
Bridgeway Capital Management
Houston,
Texas
|
-$4.6M |
| 5 |
Barclays
London,
United Kingdom
|
-$4.52M |
VIR Hedge Fund Activity: Q2 2024 in Review
215 of the 6,940 institutional investors tracked by Wall St. Rank reported a position in Vir Biotechnology (VIR) for Q2 2024, worth a combined $783M — down 13% from $901M a quarter earlier.
Buyers outnumbered sellers: 34 funds opened new VIR positions and 25 closed out — a net gain of 9 holders — while 75 added to existing stakes and 72 trimmed.
The largest buyer was OrbiMed, adding an estimated $16.1M. The largest seller was Citadel Advisors, cutting an estimated $25.5M.
- 215 institutional investors held Vir Biotechnology (VIR) as of Q2 2024, up from 209 in Q1 2024.
- Funds reported $783M of Vir Biotechnology stock for Q2 2024, down 13% quarter-over-quarter.
- 34 funds opened new Vir Biotechnology positions in Q2 2024 and 25 closed out, a net change of +9 holders.
- The largest Vir Biotechnology buyer in Q2 2024 was OrbiMed, an estimated $16.1M added.
- The largest Vir Biotechnology seller in Q2 2024 was Citadel Advisors, an estimated $25.5M sold.
Based on aggregated 13F filings for Q2 2024.